[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kriya Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643801","phase-1-rp-008-in-combination-with-daily-oral-varenicline-for-the-treatment-of-trigeminal-neuralgia-100643801",false,"NCT07596485","RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, and PRELIminary EFficacy of Percutaneous Injection of RP-008 Followed by Daily Oral Varenicline in Patients With Trigeminal Neuralgia (The RELIEF Study)","RELIEF","Inclusion Criteria:\n\n* Participant is capable of providing signed informed consent.\n* Participant must be between 18 to 80 years of age (inclusive), at the time of signing the informed consent.\n* Confirmed diagnosis of classical or idiopathic TN according to the criteria of the International Classification of Headache Disorders-3rd edition (ICHD-3, 2018).\n* The diagnosis of TN established at least 6 months prior to Screening.\n* Participant has purely unilateral pain attacks limited primarily to the maxillary (V2) and\u002For mandibular (V3) division of the trigeminal nerve.\n* Participant has failed at least 1 standard of care anti-epileptic agent (e.g., carbamazepine, oxcarbazepine, pregabalin, gabapentin, phenytoin, lamotrigine). Failure to a prior anti-epileptic medication is defined as insufficient pain relief despite use of a therapeutic dose for an adequate duration of time or being unsuitable due to contraindications or intolerance to side effects.\n* Participant is on stable dosage of any TN anti-epileptic agent(s) for a minimum of 6 weeks prior to Screening.\n\nExclusion Criteria:\n\n* Participant has bilateral TN pain attacks.\n* Participants with secondary TN, defined by ICHD-3 as TN caused by an underlying disease (e.g., tumor in the cerebellopontine angle, arteriovenous malformation, or multiple sclerosis).\n* Participants with facial pain not meeting the ICHD-3 diagnostic criteria for either classical or idiopathic TN, including: trigeminal autonomic cephalalgias, cluster headache, hemicrania continua, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).\n* Participants who had no change in pain after taking sodium channel blockers despite the use of a therapeutic dose for an adequate duration of time.","ALL","18 Years","80 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.",[29],"Trigeminal Neuralgia","RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-08","ACTUAL",{"date":36,"type":22},"2026-08",{"date":38,"type":22},"2029-02",{"name":40,"class":41},"Kriya Therapeutics, Inc.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100574953","phase-1-a-study-to-evaluate-kriya-825-vv-14295-in-adults-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100574953","NCT06765980","A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","A Phase 1\u002F2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)","VISION","Inclusion Criteria:\n\n* Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form.\n* Body mass index (BMI) of 19 to 34 kg\u002Fm2 (inclusive).\n* Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding.\n* The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening.\n* Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.\n* For study eye, Normal Luminance BCVA of 55 letters or worse using the ETDRS charts (20\u002F80 or worse) for Part 1a participants or 24 letters or better (approximately 20\u002F320 Snellen equivalent) for Part 1b and Part 2 participants.\n* Fellow eye Normal Luminance BCVA of 5 letters or better using ETDRS charts (20\u002F800 or better) for Part 1a participants or 24 letters or better (approximately 20\u002F320 Snellen equivalent or better) for Part 1b and Part 2 participants. Fellow eye must have equivalent or better visual acuity than the study eye.\n\nExclusion Criteria:\n\n* Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy secondary to a condition other than AMD; Exudative AMD diagnosis or any history of or active macular neovascularization (in study eye or fellow eye) and\u002For retinal angiomatous proliferation associated with AMD or any other cause; Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function; Active ocular or periocular infection or active uncontrolled intraocular inflammation within 3 months of Screening; History of vitrectomy, retinal detachment, or corneal transplant in the study eye; Active\u002Fhistory of uveitis.\n* Any ocular condition that prevents adequate imaging.\n* Medical, cognitive or psychiatric conditions that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.\n* Hospitalization within 1 year prior to Screening that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.\n* Any Screening test (e.g., ECG) or laboratory value (e.g., hematology) that in the opinion of the Investigator and\u002For Medical Monitor is clinically significant and renders the participant not suitable for study participation.\n* Participant has a direct contraindication to the steroid regimen (both oral and topical) or has a condition that significantly increases the risk of complication.\n* Active\u002Fhistory of malignancy within the past 5 years from Screening or any previous therapeutic radiation in the region of the study eye(s) at Screening. History of non-melanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia (CIN), and localized prostate cancer after treatment are not exclusionary.\n* Intraocular surgery (including lens replacement surgery) within 3 months prior to Screening.\n* History of laser therapy in the macular region.\n* History of intravitreal (IVT) therapy, such as IVT steroid injections, within 6 months prior to Screening.\n* COVID-19 vaccine within 90 days of Screening or plan to receive COVID-19 vaccine within 6 months of treatment.\n* Active use of systemic immunomodulatory drugs or systemic corticosteroids in the last 60 days. Topical steroids are not exclusionary.\n* Prior participation in another interventional clinical study for GA within the past 12 months from the last dosing at Screening.","55 Years",{"count":53,"type":22},62,[25,26],"The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).",[57],"Geographic Atrophy Secondary to Age-related Macular Degeneration","2026-04-29",{"date":60,"type":34},"2026-04-30",{"date":62,"type":34},"2025-05-28",{"date":64,"type":22},"2027-12-15",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":42},"100624013","phase-1-a-study-of-vv-14305-for-the-treatment-of-thyroid-eye-disease-100624013","NCT07404111","A Study of VV-14305 for the Treatment of Thyroid Eye Disease","An Adaptive Phase 1\u002F2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)","RECLAIM","Inclusion Criteria:\n\n1. Must be 18 to 80 years of age (inclusive) at Screening.\n2. Body Mass Index (BMI) of 19 to 34 kg\u002Fm2 (inclusive).\n3. Must be euthyroid (defined as normal thyroid-stimulating hormone) or have mild hyper- or hypothyroidism (being managed to bring them to a euthyroid state).\n4. Best Corrected Visual Acuity (BCVA) score of 20\u002F60 or better at Screening with no history of deterioration noted in the 3 months prior to Screening.\n5. Must be willing and able to cease product use prior to VV-14305 (or sham) peribulbar injection if using non-steroidal anti-inflammatory drug (NSAIDs), medications or any herbal supplements, vitamins, or multivitamins with antiplatelet\u002Fanticoagulant properties.\n6. The study eye and the fellow eye must fall within the pre-defined degree of proptosis and clinical activity score (CAS) as measured at Screening.\n7. Participants must be diagnosed with TED prior to Screening and be diagnosed with Graves' disease and progressive moderate to severe TED at Screening.\n\nExclusion Criteria:\n\n1. History of serious ocular condition(s) other than TED, including but not limited to uveitis, dry age-related macular degeneration (AMD), and wet AMD; Other orbital or ophthalmic diseases, including inflammatory conditions, optic neuropathy, tumors, glaucoma with visual field defect or visual field loss, that in the opinion of the Investigator and\u002For Medical Monitor is clinically significant.\n2. Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate.\n3. Diagnosed with diabetes (HbA1c ≥6.5%).\n4. History of malignancy requiring chemotherapy and\u002For radiation in the 12 months prior to Screening, except for successfully treated nonmelanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia, and localized prostate cancer.\n5. Known allergy or condition that would contraindicate the use of required study medications.\n6. Any Screening assessment or laboratory value that, in the opinion of the Investigator and\u002For Medical Monitor, is clinically significant and renders the subject not suitable for study participation.\n7. Any vaccination or planned vaccination 30 days prior to dosing, 4 weeks post dosing or during period of immunosuppression.\n8. Participant requires or, in the opinion of the Investigator, is likely to require immediate surgical ophthalmological\u002Forbital intervention or irradiation of either eye; Has had any prior surgery for TED including orbital decompression, strabismus surgery and any eyelid surgery on either eye.\n9. Prior participation in other gene therapy, investigational drug, biologic or device clinical trials within 30 days prior to Screening.",{"count":75,"type":22},110,[25,26],"The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).",[79],"Thyroid Eye Disease (TED)","NOT_YET_RECRUITING","2026-02-04",{"date":83,"type":34},"2026-02-11",{"date":85,"type":22},"2026-02",{"date":38,"type":22},{"name":40,"class":41},""]